Relief Therapeutics

Last updated
Relief Therapeutics
Type Public
Industry Biopharmaceutical
Founded2013
Headquarters Geneva, Switzerland
Key people
Raghuram Selvaraju
(Chairman)
Jack Weinstein
(Chief Financial Officer)
Products RLF-100
ACER-001
PKU GOLIKE
Sentinox
Nexodyn
Website relieftherapeutics.com

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. [1] The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016. [2]

Contents

History

Relief Therapeutics was founded in 2013 by Gael Hédou with the aim of developing new treatments for diseases with high unmet needs. [3] The company today considers itself the successor to Mondobiotech, which was founded in 2000 by Fabio Cavalli and Dorian Bevec. [4] Mondobiotech began research into Vasoactive intestinal peptide (VIP), a naturally occurring substance in humans that was first identified in the 1970s. They were granted US and European patents for a synthetic version of VIP known as aviptadil in 2006. [5]

On June 23, 2013, Mondobiotech merged with Italian pharmaceutical company Pierrel Research International to form a new Contract research organization known as Therametrics. On July 14, 2016, Therametrics merged with Relief Therapeutics to form Relief Therapeutics Holdings AG, which inherited all patents related to aviptadil. [6]

COVID-19 research

Aviptadil

In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19. [7] [8] In September 2020, Relief partnered with US-Israeli firm NRX Pharmaceuticals (formerly NeuroRx Inc) for the co-development of the drug and the co-ordination of US trials. [9] In April 2021, a reformulated version of aviptadil, known as Zyesami, was included in a National Institutes of Health (NIH) sponsored Phase 3 trial with the aim of testing aviptadil against remdesivir. [10] In May 2021, NRX submitted a request for an Emergency Use Authorization (EUA) to the US FDA for aviptadil's use in patients in intensive care. [11] [12] On 7 October 2021 Relief Therapeutics filed a lawsuit against NRX Pharmaceuticals and its CEO Dr. Jonathan Javitt in the Supreme Court of the State of New York, [13] citing multiple alleged breaches of the collaboration agreement signed by the two companies for the co-development of aviptadil. [14]

On 4 November 2021 the FDA declined EUA for the drug, but committed to working with NRX to further develop it. [15] On 29 November 2021, NRX announced that data analysis from the NIH-sponsored Phase 3 trial showed a fourfold increase in survival at 60 days for patients administered with Zyesami (Aviptadil) vs those who received placebo. [16]

Sentinox

On 27 October 2021, Applied Pharma Research (APR), a wholly-owned subsidiary of Relief, announced positive interim data from its clinical trial of Sentinox, a nasal spray aimed at reducing the viral load of patients with COVID-19, in-turn reducing the transmissibility of the virus. [17]

Other research

In October 2021, Relief announced that its collaboration partner, Texas-based Acer Therapeutics, had successfully filed for a New Drug Application with US FDA for their drug ACER-001, for the treatment of Urea Cycle Disorders (UCDs) and Maple syrup urine disease. [18]

In September 2021, APR launched a chewable tablet for the treatment of Phenylketonuria, called PKU GOLIKE KRUNCH, in Germany and Italy. [19] APR are also developing Nexodyn, a drug which aids in the management of hard-to-heal ulcers requiring long periods of treatment. [20]

Relief is actively developing RLF-100 for non-COVID-19 related acute and chronic lung diseases, such as Pulmonary sarcoidosis. [21]

Acquisitions

Related Research Articles

Pfizer American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German immigrants, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

AstraZeneca British-Swedish pharmaceutical company

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs.

Regeneron Pharmaceuticals American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

PTC Therapeutics Pharmaceutical company

PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Aviptadil Synthetic vasoactive intestinal peptide

Aviptadil is an injectable synthetic formulation of human vasoactive intestinal peptide (VIP). VIP was discovered in 1970, and has been used to treat various inflammatory conditions, such as acute respiratory distress syndrome (ARDS), asthma and chronic obstructive pulmonary disease (COPD).

Glenmark Pharmaceuticals Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha's son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India.

Actelion Swiss biopharmaceutical company

Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals

Novavax American biotechnology company

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.

Arcturus Therapeutics is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed a novel, potent, and safe RNA therapeutics platform called Lunar, a proprietary lipid-enabled delivery system for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides (ASO), and microRNA.

Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.

Cycloserine/lurasidone, developmental code name NRX-101 and tentative brand name Cyclurad, is a combination formulation of the antibiotic D-cycloserine, an antagonist of the glycine site of the NMDA receptor, and lurasidone, an atypical antipsychotic, which is under development by NeuroRx for the treatment of acute suicidal ideation/behavior (ASIB). As of May 2016, it has completed a phase II clinical trial for bipolar depression. In September 2017, the drug received fast track designation for bipolar depression from the United States Food and Drug Administration.

COVID-19 drug repurposing research Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

COVID-19 drug development Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Ultragenyx

Ultragenyx is an American biopharmaceutical company involved in the Research and Development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

References

  1. ↑ "Company, About Us". Relief Therapeutics. Retrieved January 21, 2021.
  2. ↑ "Share Details - Relief Therapeutics". SIX Swiss Exchange. Retrieved January 21, 2021.
  3. ↑ "Relief Therapeutics Announces In-Licensing Agreement to Develop and Commercialize Atexakin Alfa For the Treatment of Peripheral Neuropathies". businesswire.com. September 7, 2015. Retrieved November 5, 2021.
  4. ↑ "Mondobiotech". Archived from the original on 2012-07-20. Retrieved 2012-02-29.
  5. ↑ "655857/2021 - New York County Supreme Court". New York Supreme Court. October 7, 2021. Retrieved November 5, 2021.
  6. ↑ "THERAMetrics holding AG announces today that it expects its business combination with Relief Therapeutics SA (Relief) to be completed by mid-July 2016". Relief Therapeutics. June 28, 2016. Retrieved November 5, 2021.
  7. ↑ "Critically ill COVID-19 patients make quick recovery with treatment RLF-100". New York Post. 2 August 2020. Retrieved 3 August 2020.
  8. ↑ "Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV)". US National Library of Medicine. March 17, 2020. Retrieved January 21, 2021.
  9. ↑ Grundlehner, Werner (22 September 2020). "Schweiz: Relief Therapeutics ist wertvollstes Biotech-Unternehmen". Neue Zürcher Zeitung (in German). Retrieved 21 October 2021.
  10. ↑ "Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients begins". National Institutes of Health. April 22, 2021. Retrieved November 5, 2021.
  11. ↑ NeuroRx. "NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy". www.prnewswire.com. Retrieved 2020-09-24.
  12. ↑ "Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS". US National Library of Medicine. September 2, 2020. Retrieved January 21, 2021.
  13. ↑ Boyadjian, Rupen (12 October 2021). "Reliefs Streit wird schmutzig". Finanz und Wirtschaft (in German). Retrieved 21 October 2021.
  14. ↑ "Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)". Yahoo Finance. October 7, 2021. Retrieved October 13, 2021.
  15. ↑ "US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure". presswire.com. November 4, 2021. Retrieved November 5, 2021.
  16. ↑ "NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir". Yahoo Finance. November 29, 2021. Retrieved December 2, 2021.
  17. ↑ "Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)". Yahoo Finance. October 7, 2021. Retrieved October 13, 2021.
  18. ↑ "Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance For Filing of New Drug Application For ACER-001 To Treat Urea Cycle Disorders". Relief Therapeutics. Retrieved October 13, 2021.
  19. ↑ "Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE® KRUNCH in Germany and Italy". Relief Therapeutics. September 9, 2021. Retrieved November 5, 2021.
  20. ↑ "Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients". Relief Therapeutics. October 27, 2021. Retrieved December 2, 2021.
  21. ↑ "Relief Therapeutics - Pipeline". Relief Therapeutics. Retrieved October 13, 2021.
  22. ↑ "Relief Therapeutics to acquire FirstString Research". thepharmaletter.com. July 29, 2016. Retrieved January 21, 2021.
  23. ↑ "Relief Therapeutics takes over AdVita". Finanz und Wirtschaft. January 20, 2021. Retrieved January 21, 2021.
  24. ↑ "Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR". Biospace. May 4, 2021. Retrieved May 4, 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.